What is the optimal duration of a short-term antidepressant trial when treating geriatric depression?

Journal of Clinical Psychopharmacology
Benoit H MulsantCharles F Reynolds

Abstract

To determine the optimal duration of an antidepressant trial in elderly patients, the authors examined the probability of eventually responding to treatment based on early improvement. Four hundred seventy-two elderly patients with major depression (nonpsychotic, nonbipolar) were treated under protocolized conditions for up to 12 weeks and assessed weekly with the Hamilton Rating Scale for Depression. The probability of full response after 12 weeks of treatment was calculated in patients who had not fully responded after periods of treatment that lasted for 4 to 10 weeks. Most of the patients who had shown a partial improvement after 4 weeks of treatment became full responders after 4 or more additional weeks of treatment. By contrast, only a few of those who were nonresponders became full responders even after up to 8 additional weeks of treatment. After 4 weeks of treatment, it is possible to reliably identify a subgroup of elderly patients with depression who are more likely to benefit from a change in their treatment than from a few additional weeks of treatment with the same agent.

References

Jul 1, 1978·Archives of General Psychiatry·J Endicott, R L Spitzer
Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Jun 1, 1991·The American Journal of Psychiatry·R Guscott, P Grof
Oct 1, 1988·Journal of Clinical Psychopharmacology·S C GersonL F Jarvik
Dec 1, 1967·The British Journal of Social and Clinical Psychology·M Hamilton
Oct 1, 1995·The American Journal of Psychiatry·A A NierenbergM Fava
Dec 1, 1994·Journal of Clinical Psychopharmacology·A A NierenbergJ Sullivan
Feb 1, 1994·Journal of Clinical Psychopharmacology·S J DonovanE Tricamo
Sep 1, 1996·Archives of General Psychiatry·F M QuitkinD F Klein
Jan 22, 1996·Journal of Affective Disorders·A J Flint, S L Rifat
Oct 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F M QuitkinD F Klein
Nov 21, 1997·Archives of General Psychiatry·M E ThaseD J Kupfer
May 7, 1999·Journal of Geriatric Psychiatry and Neurology·B H Mulsant, B G Pollock
Apr 28, 2000·The American Journal of Psychiatry·W BondareffE Batzar
Sep 12, 2000·The Journal of Clinical Psychiatry·P A NewhouseC M Clary
Nov 15, 2000·The Journal of Clinical Psychiatry·A J Gelenberg, C L Chesen
Jun 26, 2001·International Journal of Geriatric Psychiatry·B H MulsantUNKNOWN PROSPECT Study Group
Dec 12, 2001·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·B H MulsantC F Reynolds
Jul 10, 2002·Journal of Affective Disorders·Ariel G GildengersCharles F Reynolds
Sep 6, 2002·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Steven P Roose, Harold A Sackeim
Apr 2, 2003·The American Journal of Psychiatry·Frederic M QuitkinDonald Klein
Jul 16, 2003·Archives of General Psychiatry·Dennis S CharneyUNKNOWN Depression and Bipolar Support Alliance
Oct 30, 2004·The American Journal of Psychiatry·Steven P RooseUNKNOWN Old-Old Depression Study Group
Jul 2, 2005·Journal of Psychiatric Practice·G S AlexopoulosR W Ross

❮ Previous
Next ❯

Citations

Nov 30, 2007·The New England Journal of Medicine·Jürgen Unützer
May 3, 2008·The American Journal of Psychiatry·Carmen AndreescuCharles F Reynolds
Sep 24, 2008·Drugs & Aging·Tarek K RajjiCharles F Reynolds
Mar 20, 2013·Canadian Pharmacists Journal : CPJ = Revue Des Pharmaciens Du Canada : RPC·Carlos Rojas-Fernandez, Mina Mikhail
Jul 20, 2014·Clinics in Geriatric Medicine·Benoit H MulsantMark J Rapoport
Jul 22, 2014·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Soham RejJordan F Karp
Apr 10, 2013·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Ian JoelUNKNOWN IRL GREY Investigative Team
May 4, 2011·The Psychiatric Clinics of North America·Carmen Andreescu, Charles F Reynolds
Jul 20, 2010·Research in Gerontological Nursing·Carlos H Rojas-FernandezCheryl A Sadowski
Jul 12, 2016·Current Treatment Options in Psychiatry·Daniel M BlumbergerZafiris J Daskalakis
Apr 24, 2012·Biometrical Journal. Biometrische Zeitschrift·Meredith L WallaceBenoit H Mulsant
Dec 1, 2009·Journal of the American Geriatrics Society·Lynn M MartireEllen M Whyte
Jun 11, 2015·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Alexander KhalafHoward Aizenstein
May 23, 2015·Current Psychiatry Reports·Verònica GálvezColleen K Loo
Mar 21, 2017·Expert Opinion on Pharmacotherapy·Kinjal PatelBenoit H Mulsant
Jan 2, 2014·Journal of Geriatric Psychiatry and Neurology·Howard J AizensteinCarmen Andreescu
May 9, 2007·International Journal of Geriatric Psychiatry·Ramin SaghafiCharles F Reynolds
Jul 5, 2007·The Annals of Pharmacotherapy·Kevin P DeSanty, Celene M Amabile
Mar 27, 2009·International Journal of Geriatric Psychiatry·Rob M KokThea J Heeren
Dec 12, 2012·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Paul A KudlowRoger S McIntyre
Jan 13, 2015·The Nurse Practitioner·Barbara J EdlundShannon J Drayton
Oct 27, 2020·Journal of Family Medicine and Primary Care·Jitendra RohillaShazia Hasan
Feb 23, 2021·Expert Opinion on Pharmacotherapy·Brett D M JonesBenoit H Mulsant

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.